Figure 2: In Vivo Assessment of LV Function

Eight to 10 weeks after IV delivery of AAV8.UCn2 or AAV8.UCn3 (1.9 × 1013 gc/kg) or saline, mice underwent physiological studies to assess LV function. (A and B) Peak rate of LV pressure development (A) (+dP/dt) and the slope of the end-systolic pressure-volume relationship (ESPVR) (B), a relatively load-independent measurement of LV contractility, were both increased by UCn2 and UCn3 gene transfer, with no between-group differences. (C and D) Peak rate of LV pressure decline (−dP/dt) (C) and the time constant of LV pressure decline (Tau) (D), measures of LV diastolic function, were both increased by UCn2 and UCn3 gene transfer, with no between-group differences. (E) Cardiac output (CO) was increased by UCn2 and UCn3 gene transfer, with no difference between UCn2 and UCn3. (F) LV developed pressure (LVP) showed no group differences. (G) Heart rate (HR) in anesthetized animals was increased by UCn2 and UCn3 gene transfer, with no between-group differences. Individual data are shown (mean ± SE); p values are from 1-way analysis of variance (ANOVA). LV = left ventricle; LVP = left ventricular developed pressure; other abbreviations as in Figure 1.